199 related articles for article (PubMed ID: 33579893)
1. Myeloma-specific superenhancers affect genes of biological and clinical relevance in myeloma.
Jia Y; Zhou J; Tan TK; Chung TH; Wong RWJ; Chooi JY; Lim JSL; Sanda T; Ooi M; De Mel S; Soekojo C; Chen Y; Zhang E; Cai Z; Shen P; Ruan J; Chng WJ
Blood Cancer J; 2021 Feb; 11(2):32. PubMed ID: 33579893
[TBL] [Abstract][Full Text] [Related]
2. Chromatin-based, in cis and in trans regulatory rewiring underpins distinct oncogenic transcriptomes in multiple myeloma.
Alvarez-Benayas J; Trasanidis N; Katsarou A; Ponnusamy K; Chaidos A; May PC; Xiao X; Bua M; Atta M; Roberts IAG; Auner HW; Hatjiharissi E; Papaioannou M; Caputo VS; Sudbery IM; Karadimitris A
Nat Commun; 2021 Sep; 12(1):5450. PubMed ID: 34521827
[TBL] [Abstract][Full Text] [Related]
3. CDK7 blockade suppresses super-enhancer-associated oncogenes in bladder cancer.
Yang Y; Jiang D; Zhou Z; Xiong H; Yang X; Peng G; Xia W; Wang S; Lei H; Zhao J; Qian Z; Wu S; Pang J
Cell Oncol (Dordr); 2021 Aug; 44(4):871-887. PubMed ID: 33905040
[TBL] [Abstract][Full Text] [Related]
4. The deubiquitinase USP7 stabilizes Maf proteins to promote myeloma cell survival.
He Y; Wang S; Tong J; Jiang S; Yang Y; Zhang Z; Xu Y; Zeng Y; Cao B; Moran MF; Mao X
J Biol Chem; 2020 Feb; 295(7):2084-2096. PubMed ID: 31822558
[TBL] [Abstract][Full Text] [Related]
5. The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma.
Choudhury SR; Ashby C; Tytarenko R; Bauer M; Wang Y; Deshpande S; Den J; Schinke C; Zangari M; Thanendrarajan S; Davies FE; van Rhee F; Morgan GJ; Walker BA
J Hematol Oncol; 2020 Aug; 13(1):108. PubMed ID: 32762714
[TBL] [Abstract][Full Text] [Related]
6. Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma.
Jiang YY; Lin DC; Mayakonda A; Hazawa M; Ding LW; Chien WW; Xu L; Chen Y; Xiao JF; Senapedis W; Baloglu E; Kanojia D; Shang L; Xu X; Yang H; Tyner JW; Wang MR; Koeffler HP
Gut; 2017 Aug; 66(8):1358-1368. PubMed ID: 27196599
[TBL] [Abstract][Full Text] [Related]
7. Super Enhancer-Mediated Upregulation of
Jia Y; Zhou J; Tan TK; Chung TH; Chen Y; Chooi JY; Sanda T; Fullwood MJ; Xiong S; Toh SHM; Balan K; Wong RWJ; Lim JSL; Zhang E; Cai Z; Shen P; Chng WJ
Cancer Res; 2022 Feb; 82(3):406-418. PubMed ID: 34893510
[TBL] [Abstract][Full Text] [Related]
8. Super-enhancer-driven TOX2 mediates oncogenesis in Natural Killer/T Cell Lymphoma.
Zhou J; Toh SH; Tan TK; Balan K; Lim JQ; Tan TZ; Xiong S; Jia Y; Ng SB; Peng Y; Jeyasekharan AD; Fan S; Lim ST; Ong CJ; Ong CK; Sanda T; Chng WJ
Mol Cancer; 2023 Apr; 22(1):69. PubMed ID: 37032358
[TBL] [Abstract][Full Text] [Related]
9. Novel insights for lncRNA MAGI2-AS3 in solid tumors.
Xue C; Li G; Lu J; Luo J; Jia J
Biomed Pharmacother; 2021 May; 137():111429. PubMed ID: 33761624
[TBL] [Abstract][Full Text] [Related]
10. MAGI2-AS3 inhibits breast cancer by downregulating DNA methylation of MAGI2.
Xu X; Yuan X; Ni J; Guo J; Gao Y; Yin W; Li F; Wei L; Zhang J
J Cell Physiol; 2021 Feb; 236(2):1116-1130. PubMed ID: 32730644
[TBL] [Abstract][Full Text] [Related]
11. Disruption of super-enhancer-driven tumor suppressor gene RCAN1.4 expression promotes the malignancy of breast carcinoma.
Deng R; Huang JH; Wang Y; Zhou LH; Wang ZF; Hu BX; Chen YH; Yang D; Mai J; Li ZL; Zhang HL; Huang Y; Peng XD; Feng GK; Zhu XF; Tang J
Mol Cancer; 2020 Aug; 19(1):122. PubMed ID: 32771023
[TBL] [Abstract][Full Text] [Related]
12. The ubiquitin-conjugating enzyme UBE2O modulates c-Maf stability and induces myeloma cell apoptosis.
Xu Y; Zhang Z; Li J; Tong J; Cao B; Taylor P; Tang X; Wu D; Moran MF; Zeng Y; Mao X
J Hematol Oncol; 2017 Jul; 10(1):132. PubMed ID: 28673317
[TBL] [Abstract][Full Text] [Related]
13. EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
Alzrigat M; Párraga AA; Agarwal P; Zureigat H; Österborg A; Nahi H; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
Oncotarget; 2017 Feb; 8(6):10213-10224. PubMed ID: 28052011
[TBL] [Abstract][Full Text] [Related]
14. Discovery platform for inhibitors of IgH gene enhancer activity.
Dolloff NG
Cancer Biol Ther; 2019; 20(4):571-581. PubMed ID: 30481117
[TBL] [Abstract][Full Text] [Related]
15. MAF functions as a pioneer transcription factor that initiates and sustains myelomagenesis.
Katsarou A; Trasanidis N; Ponnusamy K; Kostopoulos IV; Alvarez-Benayas J; Papaleonidopoulou F; Keren K; Sabbattini PMR; Feldhahn N; Papaioannou M; Hatjiharissi E; Sudbery IM; Chaidos A; Caputo VS; Karadimitris A
Blood Adv; 2023 Nov; 7(21):6395-6410. PubMed ID: 37224458
[TBL] [Abstract][Full Text] [Related]
16. ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma.
Suzuki A; Iida S; Kato-Uranishi M; Tajima E; Zhan F; Hanamura I; Huang Y; Ogura T; Takahashi S; Ueda R; Barlogie B; Shaughnessy J; Esumi H
Oncogene; 2005 Oct; 24(46):6936-44. PubMed ID: 16044163
[TBL] [Abstract][Full Text] [Related]
17. Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma.
Fulciniti M; Lin CY; Samur MK; Lopez MA; Singh I; Lawlor MA; Szalat RE; Ott CJ; Avet-Loiseau H; Anderson KC; Young RA; Bradner JE; Munshi NC
Cell Rep; 2018 Dec; 25(13):3693-3705.e6. PubMed ID: 30590042
[TBL] [Abstract][Full Text] [Related]
18. C-MAF oncogene dysregulation in multiple myeloma: frequency and biological relevance.
Rasmussen T; Knudsen LM; Dahl IM; Johnsen HE
Leuk Lymphoma; 2003 Oct; 44(10):1761-6. PubMed ID: 14692531
[TBL] [Abstract][Full Text] [Related]
19. Identification of small compounds that inhibit multiple myeloma proliferation by targeting c-Maf transcriptional activity.
Asano K; Kikuchi K; Takehara M; Ogasawara M; Yoshioka Y; Ohnishi K; Iwata A; Shimizu S; Tanaka M
Biochem Biophys Res Commun; 2023 Dec; 684():149135. PubMed ID: 37879249
[TBL] [Abstract][Full Text] [Related]
20. Pathway-based network analysis of myeloma tumors: monoclonal gammopathy of unknown significance, smoldering multiple myeloma, and multiple myeloma.
Dong L; Chen CY; Ning B; Xu DL; Gao JH; Wang LL; Yan SY; Cheng S
Genet Mol Res; 2015 Aug; 14(3):9571-84. PubMed ID: 26345890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
